HLA-DRB1*04 may predict the severity of disease in a group of Iranian COVID-19 patients

Hum Immunol. 2021 Oct;82(10):719-725. doi: 10.1016/j.humimm.2021.07.004. Epub 2021 Jul 13.

Abstract

Human leukocyte antigen (HLA) genes with extreme diversity can make a contribution for individual variations to the immune response against SARS-COV-2 infection. This study aimed to explore the distributions of HLA class II alleles frequencies and their relations with disease severity in a group of Iranian COVID-19 patients. This prospective and case-control study was conducted on 144 COVID-19 patients including 46 cases with moderate form, 54 cases with severe and 44 cases with critical disease. HLA-DRB1 and -DQB1 allele families were determined by PCR-SSP method and compared between three groups of the patients and in comparison to 153 ethnic-matched healthy controls. The patients group showed lower frequencies of HLA-DRB1*15 (OR = 0.57, P = 0.06), DRB1*15 ~ DQB1*05 haplotype (P = 0.04) and DRB1*15/DRB1*04 genotype (P = 0.04) in compare with healthy controls. Moderate COVID-19 patients had higher frequencies of HLA-DRB1*04 (P = 0.03), HLA-DRB1*10 (P = 0.05) and DRB1*04/DRB1*11 genotype (P = 0.01). Also, a higher significantly frequency of HLA-DRB1*03 allele group was observed in the critical patients versus controls (P = 0.01). Multiple logistic regression analysis revealed that the presence of DRB1*04 allele group was negatively associated with development of severe and critical disease (OR: 0.289, P = 0.005). Our results indicate a possible contribution of some HLA class II alleles in disease severity and clinical features of COVID-19 disease.

Keywords: Alleles; COVID-19; HLA-DRB1.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Alleles
  • COVID-19 / genetics*
  • Case-Control Studies
  • Female
  • Gene Frequency / genetics
  • Genotype
  • HLA-DRB1 Chains / genetics*
  • Haplotypes / genetics
  • Histocompatibility Testing / methods
  • Humans
  • Iran
  • Male
  • Middle Aged
  • Prospective Studies
  • SARS-CoV-2 / pathogenicity
  • Severity of Illness Index
  • Young Adult

Substances

  • HLA-DRB1 Chains
  • HLA-DRB1*04 antigen